Novartis Sues Sun Pharma Over Exelon ANDA

Law360, New York (July 24, 2005, 12:00 AM EDT) -- Swiss pharmaceutical giant Novartis Pharmaceuticals has sued India’s Sun Pharmaceuticals in Delaware federal court over its to make generic versions of Alzheimer treatment Exelon.

Novartis and its subsidiaries sued Sun Pharma in the U.S. District Court for the District of Delaware on July 12, court records show.

The lawsuit claims that Sun Pharma infringed a patent for the drug by filing an Abbreviated New Drug Application (ANDAs) with the U.S. Food and Drug Administration for generic versions of Exelon.

Sun Pharma filed a so-called “paragraph IV”...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.